Chinese Biotech Innovators Push Overseas as Sector Faces Reckoning
After years of falling valuations and stalled IPO activity, China’s innovative drug industry is showing early signs of a comeback. A spate of...
287 Views
A Healthy Long for Your Portfolio
Healthcare stocks tend to do better than the broad S&P 500 in risk-off environments and periods of slowing economic growth. The purchasing...
365 Views
Bristol Myers Squib & Celgene–Starboard Objections Addressed Today- Successful Deal Closure Probable
The proposed Bristol Myers Squibb Co (BMY US) & Celgene Corp (CELG US) transaction announced in the first week of 2019, garnered many sceptical...
328 Views
Bristol Myers Squib – Reaffirming Its View on Celgene Corp
The management of Bristol Myers Squibb Co (BMY US) reiterated its optimistic view regarding the acquisition of Celgene Corp (CELG US) on its Q4-18...
649 Views
Celgene and Bristol-Myers Squibb – Undervalued and Underappreciated
A dismal 2018 for the pharmaceutical and bio-tech stocks seems far in the rear view mirror. 2019 began with a bang with two blockbuster deals in...
811 Views